Navigating the Biotech Landscape

This chapter explores the journey into biotechnology, with a focus on immunometabolism and the transition to clinical development at Bikara. It highlights the establishment of a cancer-focused company and examines the significant developments in immunotherapy, particularly around checkpoint inhibitors and the tumor microenvironment. The narrative balances the optimism and challenges faced in oncology research, emphasizing innovative strategies to enhance treatment outcomes.